Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Colorectal Neoplasms
  • Epidermal Growth Factor
  • Genes, ras
  • Glycoproteins
  • Intercellular Signaling Peptides and Proteins
  • Mutation

abstract

  • Patients with tumors that have high gene expression levels of epiregulin and amphiregulin and patients with wild-type K-ras are more likely to have disease control on cetuximab treatment. The identified markers could be developed further to select patients for cetuximab therapy.

publication date

  • August 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.10.5437

PubMed ID

  • 17664471

Additional Document Info

start page

  • 3230

end page

  • 7

volume

  • 25

number

  • 22